Drug · CHEMBL516
CYPROHEPTADINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CYPROHEPTADINE. Drugs and targets, record CHEMBL516. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL516
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HRH1 | Histamine H1 receptor | Histamine H1 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3269 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials18
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02418949 | Altering Activation Patterns Post-stroke | 96 | 2021-07-13 | cyproheptadine | Its name | ClinicalTrials.gov | |
| NCT01675050 | A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain | Phase 2 | 4 | 2017-06-21 | cyproheptadine | Its name | ClinicalTrials.gov |
| NCT02568007 | Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders | Phase 4 | 4 | 2020-01-31 | cyproheptadine | Its name | ClinicalTrials.gov |
| NCT04488081 | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | Phase 2 | 1,500 | cyproheptadine | Its name | ClinicalTrials.gov | |
| NCT05087381 | Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community | Phase 4 | 1,200 | cyproheptadine | Its name | ClinicalTrials.gov | |
| NCT04979221 | Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19 | Phase 3 | 274 | cyproheptadine | Its name | ClinicalTrials.gov | |
| NCT05469165 | Serotonin Receptor Blockers in Ischemic Mitral Regurgitation | Phase 2 | 214 | cyproheptadine | Its name | ClinicalTrials.gov | |
| NCT04820751 | Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial | Phase 3 | 200 | cyproheptadine | Its name | ClinicalTrials.gov | |
| NCT04108104 | Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects | Phase 2 | 154 | cyproheptadine | Its name | ClinicalTrials.gov | |
| NCT01940978 | A Study of Combination Therapy in Children With ADHD | Phase 4 | 99 | cyproheptadine | Its name | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Cyproheptadine vs Placebo: serious adverse events | 0 of 4 | 0 of 3 | 7 | NCT01675050 |
Source Trial comparisons
Papers from its trials9
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL516
GET https://conductscience.org/api/drugs/v1/CHEMBL516/targets